Similar increases in glycolytic components and LDH have been reported in independent studies of single-cell transcriptomic changes in cortical neurons from patients with early-onset AD (7), in proteomic studies conducted on AD patients with high burden of tau pathology (5), in vulnerable brain regions of the PS19 mouse model of tauopathy/AD (4), and in cultured cells expressing human tau (32). This evidence concerns the gene MAPT and tauopathy.